SK Biopharma launches epilepsy drug in China

SK Biopharmaceuticals said Thursday it has officially launched its epilepsy drug Cenobamate in China, marking the start of full-scale commercialization in one of the world’s largest pharmaceutical markets. The drug, marketed locally as Yifurui, was approved by China’s National Medical Products Administration in December as a treatment for partial-onset seizures in adult patients. Initial prescriptions have already begun at major hospitals across the country. Cenobamate is an in-house developed t

By The Korea Herald